,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['destiny-breast04', 'breast', 'daiichisankyous']
looking forward to having our destiny-breast04 data in #her2 low metastatic #breastcancer featured during tomorrow s plenary session at #asco22. 
Daiichi Sankyo US’s channel featuring our biopharmaceutical news, passion for innovation & compassion for patients.  See our guidelines: https://t.co/4iEAbpw1Wx